The Price of a Life: Rationalising Cost-Effective Medicine
What role does NICE play? Who shapes the clinical guidelines we follow? Who determines what drugs we can prescribe and why?
YCFM Introductory Session Briefing: 'The Price of a Life'
Challenges for the pharmaceutical industry
Dr Richard Barker, Director General of the Association of the British Pharmaceutical Industry (ABPI)
Dr Richard Barker, Director General of the Association of the British Pharmaceutical Industry (ABPI)
The role of NICE
Professor Sir Michael Rawlins, Chairman, NICE
Professor Sir Michael Rawlins, Chairman, NICE
Recommended reading
- Medicines and Medical Devices Regulation: What you need to know. MHRA. 2008.
- Understanding the 2009 PPRS. Association of the British Pharmaceutical Industry. 2009.
- The Pharmaceutical Price Regulation Scheme: 10th Report to Parliament. Department of Health. 2009.
- The Pharmaceutical Price Regulation Scheme. Office of Fair Trading. 2007.
- Health Future Forum. Health Service Journal 2010.
- National Institute for Health and Clinical Excellence.
- NICE: our guidance sets the standard for good healthcare. NICE. 2008.
- National Institute for Health and Clinical Excellence: 1st Report of Session 2007/08. House of Commons Health Committee. 2007.
- A pan-European comparison regarding patient access to cancer drugs. Karolinska Institute. 2007.
- Top-up fees: 4th Report of Session 2008/09. House of Commons Health Committee. 2009.
- NICE or nasty? Has NICE eliminated the postcode lottery in prescribing? Civitas. 2004.
- Should patients be able to pay top-up fees to receive the treatment they want? BMJ debate. 2008. Yes.
- Should patients be able to pay top-up fees to receive the treatment they want? BMJ debate. 2008. No.
- High Quality Care for All: NHS Next Stage Review Final Report. Lord Darzi. Department of Health. 2008.